Saquib Ahmad: Management of DVT and Follow-Up
Saquib Ahmad, General Practitioner at Khyber Medical Centre Madinat Zyed, posted on LinkedIn:
”Management of DVT and Follow-Up
1. Initial Anticoagulation (First 3 Months)
All patients with acute DVT require therapeutic anticoagulation for a minimum of three months.
2. Treatment Duration After the First 3 Months
The decision to continue, reduce, or stop anticoagulation depends on whether the DVT was provoked, unprovoked, or associated with a persistent risk factor. This step is the key determinant of long-term outcomes.
3. Anticoagulant Options for All Acute DVT
The following medications may be used for initial treatment.
- Apixaban: 10 mg twice daily for 7 days, followed by 5 mg twice daily
- Rivaroxaban: 15 mg twice daily for 21 days, followed by 20 mg once daily
- Dabigatran: 150 mg twice daily
- Edoxaban: 60 mg once daily (started after 5 days of heparin)
- Warfarin: use only if DOAC is unsuitable
Duration: Minimum treatment duration is 3 months for all cases of DVT.
Decide Duration After 3 Months (Most Important Step)
A. Provoked DVT (temporary risk factor)
Examples: surgery, trauma, immobilization, long flight, OCPs.
• Duration: 3 months only
• No need to extend therapy
• Do NOT check D-dimer for stopping decision
Recurrence risk: very low (1–3%/year)
B. Unprovoked DVT (no clear trigger)
• Duration: Extended therapy recommended
• Either full dose or reduced-dose DOAC
• Recurrence risk high (10% in 1st year)
D-dimer use:
Check D-dimer 4-6 weeks after stopping anticoagulation
• If high → restart DOAC long term
• If normal → optional observation
C. DVT with persistent risk factor (cancer, thrombophilia, chronic disease)
• Duration: Indefinite (lifelong) anticoagulation
• D-dimer not reliable → don’t use for decisions
DOAC Dosing for Long-Term Recurrence Prevention
(AKA “secondary prevention” or “extended therapy”)
After the first 3–6 months, reduce to secondary-prevention dose:
• Apixaban 2.5 mg BID
• Rivaroxaban 10 mg daily
These doses lower recurrence by 80–90% with minimal bleeding risk.
When to Repeat D-Dimer (Very Important)
Use ONLY in unprovoked DVT when deciding whether to stop anticoagulation.
When to measure:
- 4–6 weeks after fully stopping DOAC/warfarin
- Patient should be clinically stable
- No acute illness, no post-op period (false elevation)
How to interpret:
• Normal D-dimer: Indicates low recurrence risk and it is acceptable to remain off anticoagulation, with close follow-up.
• Elevated D-dimer: Indicates high recurrence risk and anticoagulation should be restarted or continued indefinitely using a DOAC.
DO NOT repeat D-dimer:
- In provoked DVT
- In cancer
- While patient is still on anticoagulation
- During pregnancy or postpartum
- After surgery or infection (false positives)
- Courtesy MRCP UK”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch